tolvaptan has been researched along with Chronic Liver Failure in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arase, Y; Hara, T; Hirose, S; Kagawa, T; Koizumi, J; Mishima, Y; Ono, S; Sekiguchi, T; Sekiguchi, Y; Shiraishi, K; Tsuruya, K | 1 |
| Abe, Y; Hibi, T; Higashi, H; Imai, S; Itano, O; Kitagawa, Y; Kitago, M; Matsubara, K; Obara, H; Shinoda, M; Yagi, H | 1 |
| Akamatsu, N; Arita, J; Hasegawa, K; Ishizawa, T; Kaneko, J; Kiritani, S; Kokudo, N; Matsumura, M; Miyata, Y; Tamura, S | 1 |
| Chiodo, J; Gaglio, P; Marfo, K | 1 |
1 review(s) available for tolvaptan and Chronic Liver Failure
| Article | Year |
|---|---|
Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
Topics: Benzazepines; End Stage Liver Disease; Humans; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Outcome Assessment, Health Care; Tolvaptan | 2012 |
1 trial(s) available for tolvaptan and Chronic Liver Failure
| Article | Year |
|---|---|
A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: a preliminary study.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Creatinine; Diuretics; End Stage Liver Disease; Female; Humans; Liver Transplantation; Male; Middle Aged; Receptors, Vasopressin; Sodium; Tolvaptan | 2019 |
2 other study(ies) available for tolvaptan and Chronic Liver Failure
| Article | Year |
|---|---|
First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan.
Topics: Ascites; End Stage Liver Disease; Humans; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Quality of Life; Retrospective Studies; Severity of Illness Index; Tolvaptan | 2023 |
Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; End Stage Liver Disease; Female; Humans; Liver Transplantation; Living Donors; Male; Middle Aged; Tolvaptan; Transplant Recipients; Treatment Outcome | 2018 |